Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization

INSMED Inc

Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.
Underwriters granted 30-day option for up to 1,171,875 additional shares (~$112.5M).
Proceeds to fund brensocatib R&D, pre-commercial/commercial, ARIKAYCE, TPIP, INS1201, and general corporate.
Offering expected to close June 13, 2025; joint book-runners: Goldman Sachs, Leerink, BofA, Jefferies, J.P. Morgan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.